DNDi aims to deliver:
- A safe, effective, and easy-to-use direct-acting antiviral regimen, to be used as an affordable combination paving the way for a public health approach to HCV.
- Increased access to affordable treatments by supporting policy change and encouraging political will to treat HCV.
- Innovative programmes to improve access to HCV diagnosis and treatment in a variety of countries.
The current hepatitis C portfolio includes:
Ravidasvir / Sofosbuvir
For more details on each project, see DNDi‘s Global Portfolio